Kaposiform hemangioendothelioma with Kasabach-Merritt syndrome: a new indication for propranolol treatment

Authors :: Hermans, D.J.J.
Beynum, I.M. van
Vijver, R.J. van der
Schultze Kool, L.J.
Blaauw, I. de
Vleuten, C.J.M. van der
Hermans, D.J.J.
Beynum, I.M. van
Vijver, R.J. van der
Schultze Kool, L.J.
Blaauw, I. de
Vleuten, C.J.M. van der
Source :: Journal of Pediatric Hematology/Oncology; e171; 3; 1077-4114; 4; 33; ~Journal of Pediatric Hematology/Oncology~e171~3~~~1077-4114~4~33~~
Publication Year :: 2011
Abstract: Contains fulltext : 98048.pdf (publisher's version ) (Closed access)<br />Kaposiform hemangioendothelioma is a rare vascular tumor in children. Especially, in association with the Kasabach-Merritt Phenomenon it can be life threatening. The management of these patients is very difficult and an aggressive treatment regime is required. Several multimodality and chemotherapeutic regimens have been described but with variable success and many side effects. We present a 6-week-old boy with Kaposiform hemangioendothelioma and Kasabach-Merritt Phenomenon. Ongoing propranolol treatment with only 4 initial courses of vincristine resulted in a remission that lasted at least 1 year.

Database :: OAIster
Journal :: Journal of Pediatric Hematology/Oncology; e171; 3; 1077-4114; 4; 33; ~Journal of Pediatric Hematology/Oncology~e171~3~~~1077-4114~4~33~~
Publication Type :: Electronic Resource
Accession number :: edsoai.on1284032701
Document Type :: Electronic Resource

Tools